Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) COO Anish Patel sold 4,875 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $15.11, for a total value of $73,661.25. Following the sale, the chief operating officer now owns 12,347 shares of the company’s stock, valued at approximately $186,563.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Anish Patel also recently made the following trade(s):

  • On Monday, January 22nd, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.13, for a total value of $73,758.75.
  • On Tuesday, January 2nd, Anish Patel sold 11,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $165,000.00.
  • On Tuesday, December 26th, Anish Patel sold 102 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.01, for a total value of $1,531.02.
  • On Friday, December 22nd, Anish Patel sold 983 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.03, for a total value of $14,774.49.

Enliven Therapeutics Stock Up 3.5 %

Shares of Enliven Therapeutics stock opened at $15.95 on Friday. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $25.34. The business has a fifty day simple moving average of $13.62 and a 200 day simple moving average of $14.06. The stock has a market cap of $657.30 million, a PE ratio of 4.98 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). Analysts expect that Enliven Therapeutics, Inc. will post -2.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Enliven Therapeutics by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 158,440 shares of the company’s stock worth $2,193,000 after purchasing an additional 1,809 shares during the period. AJOVista LLC acquired a new position in Enliven Therapeutics in the fourth quarter valued at about $28,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after acquiring an additional 1,029 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Enliven Therapeutics in the fourth quarter valued at about $66,000. Finally, SG Americas Securities LLC grew its stake in Enliven Therapeutics by 17.8% in the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after acquiring an additional 2,041 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Read More

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.